Shares of clinical-stage biotechnology company Recursion Pharmaceuticals (NASDAQ: RXRX) soared 11.43% on Wednesday, significantly outperforming the broader market. The rally followed a major analyst ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

An exercise-driven course on Advanced Python Programming that was battle-tested several hundred times on the corporate-training circuit for more than a decade. Written by David Beazley, author of the ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, Rallybio Corporation (NASDAQ:RLYB) announced a definitive agreement to sell ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of These 10 Stocks Are Making Big Moves. Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news ...

35 x 27.5 cm. (13.8 x 10.8 in.) Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...